Install
Where the world charts, chats and trades markets. We're a supercharged super-charting platform and social network for traders and investors. Free to sign up.
- 20,976articles · 30d
- 1+ hour agolatest article
- Aug 15, 2026earliest in window
- 94%with images · 8 videos
- 143avg words
- business 12,005
- markets 9,924
- stock 6,965
- tmt newswire 5,411
- globenewswire 4,854
- finance 4,645
- technology 3,234
- stocks 3,054
- 2026 2,821
- economy 2,535
- business news 2,220
- earnings 2,160
- autre 1,974
- investing 1,801
- artificial intelligence 1,731
- politics 1,715
- (midwest communications 1,523
- europe 1,467
- united states 1,301
- ai 1,300
- Economy, Business & Finance 19,836
- Finance & Business 19,152
- News 11,611
- Finance 5,361
- Business & Industrial 2,237
- Industrial 596
- Health & Wellness 350
- Politics 263
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
RCKT: Gene therapy pipeline advances with pivotal Danon trial, KRESLADI launch, and robust patient outreach
3+ day, 11+ hour ago (80+ words) TradingView The company is advancing gene therapies for rare cardiomyopathies, with a pivotal Danon trial underway and a Q4 launch for KRESLADI. Patient identification is improving through genetic testing initiatives and community outreach, while safety and efficacy are being optimized via…...
Legal profession is ‘detrimental’ to mental health, say 41% of lawyers
3+ day, 12+ hour ago (23+ words) TradingView Legal profession is ‘detrimental’ to mental health, say 41% of lawyers...
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
3+ day, 18+ hour ago (406+ words) TradingView Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in…...
SLDB: Pivotal gene therapy data and regulatory milestones for DMD and FA expected in early 2025
4+ day, 9+ hour ago (75+ words) TradingView The company is advancing gene therapies for DMD and FA, with high demand and robust clinical progress. Novel delivery platforms and optimized constructs drive strong safety and efficacy signals, with pivotal data and regulatory updates expected by early next…...
SPTX: Glyph platform enables novel oral therapies for depression and anxiety, advancing toward pivotal trials
4+ day, 11+ hour ago (82+ words) TradingView SPTX: Glyph platform enables novel oral therapies for depression and anxiety, advancing toward pivotal trials The company presented its neuroscience-focused pipeline, highlighting the Glyph platform's ability to overcome oral bioavailability and liver toxicity issues. Lead programs GlyphAllo and GlyphAgo…...
IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement
4+ day, 13+ hour ago (85+ words) TradingView IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement The phase I/II trial of OPGX-BEST1 gene therapy in BVMD and ARB showed strong safety and promising efficacy, with all participants experiencing functional gains and…...
Three jurors in Lindsay Clancy's US murder trial point fingers at holdout after mistrial
4+ day, 15+ hour ago (29+ words) TradingView Three jurors in Lindsay Clancy's US murder trial point fingers at holdout after mistrial...
IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement — TradingView News
4+ day, 16+ hour ago (81+ words) IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement TradingView IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement The phase I/II trial of OPGX-BEST1 in BVMD and ARB…...
Meta, States Have Discussed Settling Teen Social Media Harm Case - Bloomberg News
2+ week, 5+ day ago (25+ words) TradingView Meta, States Have Discussed Settling Teen Social Media Harm Case - Bloomberg News...
Key facts: META faces $1T lawsuit; $130–145B capex; 29-state suit
2+ week, 5+ day ago (196+ words) TradingView Key facts: META faces $1T lawsuit; $130–145B capex; 29-state suit - Pending lawsuit up to $1 trillion clouds Meta Platforms (META). Traders note no way to pass costs to users; a settlement could boost shares short-term but may spur more suits. - META plans…...